AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

ASX:PABPatrys Stock Price, Forecast & News

A$0.01
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.01
Now: A$0.01
A$0.01
50-Day Range N/A
52-Week Range
A$0.01
Now: A$0.01
A$0.04
Volume250,000 shs
Average VolumeN/A
Market Capitalization$12.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Patrys Limited, a biopharmaceutical company, develops products for the treatment of cancer in Australia. The company develops PAT-SM6, a natural human antibody that is in Phase I/IIa clinical trials used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers, such as multiple myeloma; and PAT-SC1, a clinical trial antibody that treats gastric cancer. It also develops PAT-LM1, a natural human antibody that is used for the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10, a lupus autoantibody that penetrates live cell nuclei by binding to DNA or its precursors outside of cells and then following it into cell nuclei through a nucleoside transporter. The company was founded in 2006 and is based in South Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9692 7222

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$746,241.00
Cash FlowA$0.01 per share
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares1,072,590,016
Market Cap$12.87 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PAB News and Ratings via Email

Sign-up to receive the latest news and ratings for PAB and its competitors with MarketBeat's FREE daily newsletter.

Patrys (ASX:PAB) Frequently Asked Questions

How were Patrys' earnings last quarter?

Patrys Limited (ASX:PAB) issued its earnings results on Wednesday, February, 20th. The company reported $0.00 EPS for the quarter. View Patrys' earnings history.

Has Patrys been receiving favorable news coverage?

News stories about PAB stock have been trending very negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Patrys earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutPatrys.

Who are some of Patrys' key competitors?

What other stocks do shareholders of Patrys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Patrys investors own include Woolworths Group (WOW), Proteomics Int Lab (PIQ), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

Who are Patrys' key executives?

Patrys' management team includes the following people:
  • Dr. James A. Campbell Ph.D., MBA, MD, CEO & Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 46)
  • Dr. Deanne Greenwood GAICD, Ph.D., MBA, VP of Bus. Devel. & Intellectual Property

What is Patrys' stock symbol?

Patrys trades on the ASX under the ticker symbol "PAB."

What is Patrys' stock price today?

One share of PAB stock can currently be purchased for approximately A$0.01.

How big of a company is Patrys?

Patrys has a market capitalization of $12.87 million and generates $746,241.00 in revenue each year.

What is Patrys' official website?

The official website for Patrys is www.patrys.com.

How can I contact Patrys?

The company can be reached via phone at 61 3 9692 7222.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.